BCTXW
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$0.00
−0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 110.6K | 147.9K | 114.0K | 20.5K | 19.4K |
| Gross Profit | (110.6K) | (147.9K) | (114.0K) | (20.5K) | (19.4K) |
| Operating Expenses | |||||
| R&D Expense | 28.1M | 29.5M | 37.5K | 15.3M | 10.3K |
| SG&A Expense | 6.8M | 8.1M | 9.2K | 7.9M | 7.3M |
| General & Admin Expense | 4.7M | — | 8.5K | 7.9M | 7.3M |
| Selling & Marketing Expense | — | — | 685.30 | — | — |
| Other Expenses | 3.2M | — | (685.00) | (763.00) | (396.00) |
| Total Operating Expenses | 38.1M | 37.6M | 46.0K | 23.3M | 19.6K |
| Cost and Expenses | 41.4M | 37.7M | 46.0K | 23.3M | 15.3M |
| Operating Income (EBIT) | (41.4M) | (37.7M) | (46.0K) | (23.3M) | (15.3M) |
| Non-Operating | |||||
| Interest Income | 512.9K | 166.4K | 391.5K | 891.2K | 136.7K |
| Interest Expense | 66.6K | 51.3K | — | — | 979.00 |
| Net Interest Income | 449.4K | 115.1K | 391.5K | — | 135.8K |
| Other Non-Op Income/Expense | 1.3M | 899.7K | 39.2K | 3.0M | (11.7M) |
| Non-Operating Income (excl Interest) | (949.5K) | (951.0K) | — | 4.0M | 18.8M |
| EBT (Pre-Tax Income) | (40.1M) | (36.8M) | (6.8K) | (20.3M) | (26.8M) |
| Income Tax Expense | 171.9K | — | — | (153.0K) | 30.7K |
| Bottom Line | |||||
| Net Income | (46.8M) | (36.5M) | (6.6K) | (20.3M) | (11.6M) |
| Earnings from Cont. Ops | (47.3M) | (36.8M) | (6.8K) | (27.2M) | (34.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.5M) | (36.5M) | (6.5M) | (26.8K) | (34.4K) |
| Per Share | |||||
| Basic EPS | ($14.83) | ($86.25) | ($4.28) | ($19.79) | ($25.70) |
| Diluted EPS | ($14.83) | ($86.25) | ($4.28) | ($19.79) | ($25.70) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 7.3M | 423114 | 1.1M | 1.0M | 1.0M |
| Diluted Shares Outstanding | 7.3M | 423114 | 1.1M | 1.0M | 1.0M |
| Profitability Metrics | |||||
| EBITDA | (40.3M) | (36.6M) | (45.9K) | (27.2M) | (34.0M) |
| D&A | 143.6K | 147.9K | 115.84 | 15.3K | 15.3K |
| EBIT | (40.4M) | (36.8M) | (46.0K) | (27.2M) | (34.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026